VANCOUVER, BRITISH COLUMBIA -- Variational AI announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significant improvements in algorithmic performance and target coverage through platform architecture design, as well as extending its application to degraders, PROTACs, glues, and novel payload design for antibody drug conjugates (ADCs) and related modalities.

“Enki 4 is a massive step forward for our platform,” said Ali Saberali, Co-Founder & Head of Platform at Variational AI. “We’ve re-architected Enki and improved the underlying algorithms to expand target and modality coverage, while operating faster to deliver even better performance for our partners.”

Enki 4 now supports the rapid generation of novel, potent, selective, and synthesizable lead-like structures pre-trained on 760 drug targets, a 28% increase over the previous Enki version’s 592 targets, with more to be released soon. The update delivers enhanced performance across more than 12 target classes, including: GPCRs, kinases, ion channels, proteases, oxidoreductases, hydrolases, and others.

“This Enki release continues our process of continuous model innovation” added Handol Kim, Co-Founder & CEO. “Enki 4 enables our biotech partners to start with novel leads they would not have discovered using traditional methods. Our goal is to eliminate hit ID and hit-to-lead, generating molecules ready to go directly into lead optimization.”